New Monoclonal Antibodies to Mesothelin Useful for Immunohistochemistry, Fluorescence-Activated Cell Sorting, Western Blotting, and ELISA

Purpose: Mesothelin is a cell surface protein that is highly expressed in some malignant tumors, and is a promising target for immunotherapy. Recent data suggests that mesothelin is an adhesive protein and may have a role in the metastases of ovarian cancer. Although a few monoclonal antibodies (MAb) to mesothelin have been produced, they have limitations for the study of expression of native mesothelin because of their low affinity or reactivity only with denatured mesothelin protein. We have produced novel MAbs to mesothelin to help study mesothelin function and to develop improved diagnosis and immunotherapy of mesothelin-expressing tumors. Experimental Design: Mesothelin-deficient mice were immunized with plasmid cDNA encoding mesothelin, and boosted with a mesothelin-rabbit IgG Fc fusion protein prior to cell fusion. Hybridomas were screened by an ELISA using plates coated with mesothelin-Fc protein. Results: Seventeen hybridomas producing anti-mesothelin antibodies were established and shown to react with two epitopes on mesothelin. One group reacts with the same epitope as the low affinity antibody K1 that was originally used to identify mesothelin. The other is a new group that reacts with a new epitope. One antibody from each group was chosen for further study and shown to react strongly on ELISA, on immunohistochemistry, and by fluorescence-activated cell sorting on living cells. Conclusion: Our two newly established MAbs, MN and MB, have different and useful properties compared with current antibodies used for the detection of mesothelin by immunohistochemistry, fluorescence-activated cell sorting, ELISA, and Western blotting.

[1]  G. Reynolds,et al.  Demystified … , 2000 .

[2]  I. Pastan,et al.  111Indium‐labeled monoclonal antibody K1: Biodistribution study in nude mice bearing a human carcinoma xenograft expressing mesothelin , 1999, International journal of cancer.

[3]  J. Cameron,et al.  Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  J. Bausch,et al.  Monoclonal antibodies. , 1990, Bioprocess technology.

[5]  R. Odze,et al.  Immunohistochemistry Can Help Distinguish Metastatic Pancreatic Adenocarcinomas From Bile Duct Adenomas and Hamartomas of the Liver , 2005, The American journal of surgical pathology.

[6]  I. Pastan,et al.  Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[7]  I. Pastan,et al.  Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[8]  I. Pastan,et al.  Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  I. Pastan,et al.  Mesothelin Is Not Required for Normal Mouse Development or Reproduction , 2000, Molecular and Cellular Biology.

[10]  Z. Ye,et al.  Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[11]  James J. Vincent,et al.  Lowering the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting antitumor activity. , 2001, Cancer research.

[12]  I. Pastan,et al.  Novel anti-CD30 recombinant immunotoxins containing disulfide-stabilized Fv fragments. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  I. Pastan,et al.  Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium , 1992, International journal of cancer.

[14]  W. Wilson,et al.  Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. , 2001, The New England journal of medicine.

[15]  D. Cao,et al.  Expression of Mesothelin, Fascin, and Prostate Stem Cell Antigen in Primary Ovarian Mucinous Tumors and Their Utility in Differentiating Primary Ovarian Mucinous Tumors From Metastatic Pancreatic Mucinous Carcinomas in the Ovary , 2005, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[16]  K. Bernstein,et al.  Nucleotide sequence of a rabbit IgG heavy chain from the recombinant F-I haplotype , 2004, Immunogenetics.

[17]  N. Ordóñez,et al.  Application of Mesothelin Immunostaining in Tumor Diagnosis , 2003, The American journal of surgical pathology.

[18]  I. Pastan,et al.  Localization of Mesothelin in Epithelial Ovarian Cancer , 2005, Applied immunohistochemistry & molecular morphology : AIMM.

[19]  Ira Pastan,et al.  Mesothelin: a new target for immunotherapy. , 2004, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  I. Pastan,et al.  Monoclonal Antibody K1 Reacts With Epithelial Mesothelioma but not With Lung Adenocarcinoma , 1992, The American journal of surgical pathology.

[21]  D. Faigel,et al.  Novel Markers of Pancreatic Adenocarcinoma in Fine-Needle Aspiration: Mesothelin and Prostate Stem Cell Antigen Labeling Increases Accuracy in Cytologically Borderline Cases , 2003, Applied immunohistochemistry & molecular morphology : AIMM.

[22]  A. Musk,et al.  Mesothelin-family proteins and diagnosis of mesothelioma , 2003, The Lancet.

[23]  N Urban,et al.  Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. , 2004, Gynecologic oncology.

[24]  I. Pastan,et al.  Analysis of cloned Fvs from a phage display library indicates that DNA immunization can mimic antibody response generated by cell immunizations. , 1999, Journal of immunological methods.

[25]  Y. Sugisaki,et al.  Reversing the Effects of Formalin Fixation with Citraconic Anhydride and Heat: A Universal Antigen Retrieval Method , 2005, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[26]  R. Hruban,et al.  Mesothelin-specific CD8+ T Cell Responses Provide Evidence of In Vivo Cross-Priming by Antigen-Presenting Cells in Vaccinated Pancreatic Cancer Patients , 2004, The Journal of experimental medicine.

[27]  I. Pastan,et al.  Rapid grouping of monoclonal antibodies based on their topographical epitopes by a label-free competitive immunoassay. , 2004, Journal of immunological methods.

[28]  N. Umesaki,et al.  Binding of Ovarian Cancer Antigen CA125/MUC16 to Mesothelin Mediates Cell Adhesion* , 2004, Journal of Biological Chemistry.

[29]  N. Ordóñez Value of Mesothelin Immunostaining in the Diagnosis of Mesothelioma , 2003, Modern Pathology.